Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
S095029
- Development stage
- Phase 2
- Lead developer
- Servier Bio-Innovation LLC
- Modality
- Vaccines & Immunotherapeutics, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
S095029 is a clinical-stage monoclonal antibody that targets NKG2A (killer cell lectin-like receptor C1), an inhibitory receptor expressed on natural killer (NK) cells and some T cells. By blocking NKG2A, S095029 is designed to enhance anti-tumor immune responses by preventing the interaction between NKG2A and its ligand HLA-E. This blockade releases the inhibition of NK and CD8+ T cells, potentially increasing their cytotoxic activity against tumor cells. The antibody has been engineered with an Fc-silenced backbone to minimize unwanted immune activation through Fc-mediated effector functions[9][5]. It is being developed primarily for use in combination with other immunotherapies such as pembrolizumab (anti-PD-1) or cemiplimab (anti-PD-1), particularly in advanced solid tumors including metastatic non-small cell lung cancer and gastroesophageal junction/gastric adenocarcinoma[4][6][8]. The drug was originally developed by Adir SRL and Symphogen (a subsidiary of Servier), with current development led by Servier Bio-Innovation LLC[5].
- Other names
- anti-nkg2a monoclonal antibody sym025anti-nkg-2a monoclonal antibody sym025anti-nkg 2a monoclonal antibody sym025
02
Targets
KLRC1 (Killer cell lectin-like receptor subfamily C member 1)
Beyond the preview
Go deeper on S095029.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on S095029.